Flomics Biotech continues to dedicate resources in the battle against the COVID19 pandemic. Last year Flomics announced the release of -FlomicsCOVID19– a cloud-based Next Generation Sequencing (NGS) platform for fast and automated analysis of COVID-19 NGS samples data, and new updates are currently available including the detection of the novel SARS-Cov-2 variants: Delta, Lambda, Mu.

Flomics has joined forces with international biotech partners, specialized in NGS tests, for the development of the aforementioned cloud-based data analysis solution for COVID-19 detection and research. Combining the unique features of the different experimental sequencing kits available for SARS-CoV-2 detection (either metagenomics or amplicon based), Flomics platform maximizes the information extracted from each single experiment performed in a reliable, sensitive and automated way. FlomicsCOVID19 helps hospitals, clinics and research laboratories in transforming raw data into interpretable clinical information that will help manage this pandemic, without the need for computational infrastructures or bioinformatics expertise. It takes NGS raw data and automatically performs quality control, taxonomy quantification, variant calling and interpretation, virus variant identification, viral load calculation, everything on the cloud.

Dr. Joao Curado, CEO of Flomics Biotech, said “we decided to enter the new market this pandemic created to build a completely novel custom-made product that combines our expertise in the genomics field and RNA analysis with an urge to make it available to hospitals and diagnosis laboratories in a simple, straightforward and efficient way. We see a lot of interest today from different international partners in the identification of the new COVID-19 viral variants such as delta and mu, helping them understand how the disease is evolving in their local communities.”

FlomicsCOVID19 combines state-of-the art bioinformatics tools with an unique and simple to use graphical interface that makes it the easiest option in the market to enable NGS testing and analysis in any healthcare facility in the world. Since it is completely integrated in Amazon Web Services (AWS), the platform is scalable and ensures reproducibility independently of the number or size of the samples.